Amit Kaushik1, Chhavi Gupta1, Stefanie Fisher2, Elizabeth Story-Roller1, Christos Galanis1, Nicole Parrish2,3, Gyanu Lamichhane1,3. 1. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA. 2. Department of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA. 3. Taskforce to study Resistance Emergence & Antimicrobial development Technology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA.
Abstract
AIM: The objective of this study was to assess if avibactam, a new β-lactamase inhibitor, can restore the potency of carbapenems, a sub-class of β-lactams, against Mycobacterium abscessus clinical isolates. MATERIALS & METHODS: 28 M. abscessus clinical isolates that are resistant to multiple drugs currently used to treat its infection were included. MIC of carbapenems alone and in combination with avibactam against these strains were determined. RESULTS: Tebipenem, an oral carbapenem, and ertapenem and panipenem exhibited the greatest shift in MIC when supplemented with avibactam. CONCLUSION: Avibactam restores MICs of tebipenem, ertapenem and panipenem against M. abscessus to therapeutically achievable concentrations and raises the possibility of usefulness of these carbapenems to treat drug-resistant M. abscessus infections.
AIM: The objective of this study was to assess if avibactam, a new β-lactamase inhibitor, can restore the potency of carbapenems, a sub-class of β-lactams, against Mycobacterium abscessus clinical isolates. MATERIALS & METHODS: 28 M. abscessus clinical isolates that are resistant to multiple drugs currently used to treat its infection were included. MIC of carbapenems alone and in combination with avibactam against these strains were determined. RESULTS:Tebipenem, an oral carbapenem, and ertapenem and panipenem exhibited the greatest shift in MIC when supplemented with avibactam. CONCLUSION:Avibactam restores MICs of tebipenem, ertapenem and panipenem against M. abscessus to therapeutically achievable concentrations and raises the possibility of usefulness of these carbapenems to treat drug-resistant M. abscessus infections.
Authors: D Rebecca Prevots; Pamela A Shaw; Daniel Strickland; Lisa A Jackson; Marsha A Raebel; Mary Ann Blosky; Ruben Montes de Oca; Yvonne R Shea; Amy E Seitz; Steven M Holland; Kenneth N Olivier Journal: Am J Respir Crit Care Med Date: 2010-06-10 Impact factor: 21.405
Authors: Amit Kaushik; Nicole C Ammerman; Nicole M Parrish; Eric L Nuermberger Journal: Antimicrob Agents Chemother Date: 2019-08-23 Impact factor: 5.191
Authors: Michelle H Larsen; Karen Lacourciere; Tina M Parker; Alison Kraigsley; Jacqueline M Achkar; Linda B Adams; Kathryn M Dupnik; Luanne Hall-Stoodley; Travis Hartman; Carly Kanipe; Sherry L Kurtz; Michele A Miller; Liliana C M Salvador; John S Spencer; Richard T Robinson Journal: Tuberculosis (Edinb) Date: 2020-02-11 Impact factor: 3.131
Authors: Khalid M Dousa; Sebastian G Kurz; Magdalena A Taracila; Tracey Bonfield; Christopher R Bethel; Melissa D Barnes; Suresh Selvaraju; Ayman M Abdelhamed; Barry N Kreiswirth; W Henry Boom; Shannon H Kasperbauer; Charles L Daley; Robert A Bonomo Journal: Antimicrob Agents Chemother Date: 2020-07-22 Impact factor: 5.191
Authors: Pankaj Kumar; Varsha Chauhan; José Rogério A Silva; Jerônimo Lameira; Felipe B d'Andrea; Shao-Gang Li; Stephan L Ginell; Joel S Freundlich; Cláudio Nahum Alves; Scott Bailey; Keira A Cohen; Gyanu Lamichhane Journal: Antimicrob Agents Chemother Date: 2017-09-22 Impact factor: 5.191